Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors

被引：0
|
作者：
Eiki Ichihara
Daijiro Harada
Koji Inoue
Takuo Shibayama
Shinobu Hosokawa
Daizo Kishino
Shingo Harita
Nobuaki Ochi
Naohiro Oda
Naofumi Hara
Katsuyuki Hotta
Yoshinobu Maeda
Katsuyuki Kiura
机构：
[1] Okayama University Hospital,Department of Allergy and Respiratory Medicine
[2] National Hospital Organization Shikoku Cancer Center,Department of Thoracic Oncology
[3] Ehime Prefectural Central Hospital,Department of Respiratory Medicine
[4] National Hospital Organization Okayama Medical Center,Department of Respiratory Medicine
[5] Japanese Red Cross Okayama Hospital,Department of Respiratory Medicine
[6] Himeji Red Cross Hospital,Department of Respiratory Medicine
[7] Okayama Saiseikai General Hospital,Department of Internal Medicine
[8] Kawasaki Medical School,Department of General Internal Medicine 4
[9] Fukuyama City Hospital,Department of Internal Medicine
[10] Okayama University Graduate School of Medicine,Department of Hematology, Oncology and Respiratory Medicine
[11] Dentistry,Center for Innovative Clinical Medicine
[12] and Pharmaceutical Sciences,undefined
[13] Okayama University Hospital,undefined
来源：
Cancer Immunology, Immunotherapy | 2021年 / 70卷
关键词：
Non-small-cell lung cancer; Immune checkpoint inhibitor; EGFR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：101 / 106
页数：5
相关论文
共 50 条
  • [41] Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non-small-cell lung cancer (TREBLE).
    Johnson, Melissa Lynne
    Miller, Vincent A.
    Patel, Suraj
    Zhao, Yumin
    Cheng, Li
    Ali, Siraj Mahamed
    Wooten, Michael
    Daniel, Davey B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] A differential analysis of TCR repertoire between patients with EGFR-mutant and KRAS-mutant non-small-cell lung cancer
    Xie, Yuancai
    Li, Yingmei
    Dong, Linfeng
    Chen, Shifu
    Liu, Jixian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    [J]. ONCOLOGY, 2014, 86 (02) : 86 - 93
  • [44] Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer
    Zachary A. Yochum
    Jessica Cades
    Hailun Wang
    Suman Chatterjee
    Brian W. Simons
    James P. O’Brien
    Susheel K. Khetarpal
    Ghali Lemtiri-Chlieh
    Kayla V. Myers
    Eric H.-B. Huang
    Charles M. Rudin
    Phuoc T. Tran
    Timothy F. Burns
    [J]. Oncogene, 2019, 38 : 656 - 670
  • [45] Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors
    Pilotto, Sara
    Bria, Emilio
    [J]. LUNG CANCER MANAGEMENT, 2013, 2 (02) : 89 - 92
  • [46] Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer
    Yochum, Zachary A.
    Cades, Jessica
    Wang, Hailun
    Chatterjee, Suman
    Simons, Brian W.
    O'Brien, James P.
    Khetarpal, Susheel K.
    Lemtiri-Chlieh, Ghali
    Myers, Kayla V.
    Huang, Eric H. -B.
    Rudin, Charles M.
    Tran, Phuoc T.
    Burns, Timothy F.
    [J]. ONCOGENE, 2019, 38 (05) : 656 - 670
  • [47] Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer
    Reinhorn, Daniel
    Jacobi, Oded
    Icht, Oded
    Dudnik, Elizabeth
    Rotem, Ofer
    Zer, Alona
    Goldstein, Daniel A.
    [J]. IMMUNOTHERAPY, 2020, 12 (04) : 235 - 243
  • [48] Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?
    Mok, Tony S. K.
    Loong, Herbert H.
    [J]. LANCET, 2016, 387 (10027): : 1488 - 1490
  • [49] Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
    Giri, Anshu
    Walia, Simrit S.
    Gajra, Ajeet
    [J]. REVIEWS ON RECENT CLINICAL TRIALS, 2016, 11 (04) : 297 - 305
  • [50] Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study)
    Okuma, Yusuke
    Nomura, Shogo
    Ninomiya, Kiichiro
    Gyotoku, Hiroshi
    Murakami, Shuji
    Kogure, Yoshihito
    Harada, Daijiro
    Okishio, Kyoichi
    Okamoto, Hiroaki
    Goto, Yasushi
    [J]. FUTURE ONCOLOGY, 2023, : 1515 - 1521
12345